簡(jiǎn)要描述:
YY0283RAnti-P2Y1 receptor P2Y1受體抗體50ug/100ug
更新時(shí)間:2024-08-18;廠商性質(zhì):經(jīng)銷(xiāo)商;覽量:1715
YY0283R Anti-P2Y1 receptor P2Y1受體抗體 50ug/100ug
YY1118R Anti-Tenascin/TN 細(xì)胞粘合素抗體 50ug/100ug
YY0535R Anti-TFF3 (trefoil factor3) 三葉肽因子3抗體 50ug/100ug
YY1144R Anti-TFPI-2 (tissue factor pathway in hibitor-2) 組織因子途徑抑制劑-2抗體 50ug/100ug
YY0066R Anti-TGF-α (Ttansforming Growth Factor –α) 轉(zhuǎn)移生長(zhǎng)因子–α抗體 50ug/100ug
YY0103R Anti-TGF-β1(Ttansforming Growth Factor –β1) 轉(zhuǎn)移生長(zhǎng)因子–β1抗體 50ug/100ug
YY0100R Anti-TGF-β2 (Ttansforming Growth Factor –β2) 轉(zhuǎn)移生長(zhǎng)因子–β2抗體 50ug/100ug
YY0099R Anti-TGF-β3(Ttansforming Growth Factor –β3) 轉(zhuǎn)移生長(zhǎng)因子–β3抗體 50ug/100ug
YY0117R Anti-TGF-βR 2(Transforming growth factor β receptor 2 ) 轉(zhuǎn)移生長(zhǎng)因子–β受體2抗體 50ug/100ug
YY0638R Anti-TGF-βR1/ALK (TGF-beta receptor type I) 轉(zhuǎn)移生長(zhǎng)因子–β受體1抗體 50ug/100ug
YY0632R Anti-Thioster-containing protein 1(Anti-Anopheles stephensi protein 1) 硫酯包含蛋白-1抗體 50ug/100ug
YY0283R Anti-P2Y1 receptor P2Y1受體抗體 50ug/100ug
YY1276R anti-Thioredoxin 1(ERdj5) 硫氧還蛋白抗體 50ug/100ug
YY0778R Anti-Thy-1/CD90 CD90抗體 50ug/100ug
YY0226R Anti-Thymosin α-1 胸腺肽 α-1抗體 50ug/100ug
YY0706G Anti-Thyroxine(T4)/Tg4-Ab (Thyroglobulin 4 Antibody) 甲狀腺素T4抗體 50ug/100ug
YY1300R anti-Tie2(Porcine tyrosine kinase with immunoglobulin-like and EGF-like domains 2) 上皮生長(zhǎng)因子樣域酪氨酸激酶2 50ug/100ug
YY0640R Anti-TIGAR humen (TP53- induced glycolysis and apoptosis-regulator ) 兔抗人TIGAR蛋白抗體 50ug/100ug
YY0415R Anti-TIMP-1(Tissue Inhibitor of Metalloproteinase-1) 金屬蛋白酶組織抑制因子-1抗體 50ug/100ug
YY0416R Anti-TIMP-2(Tissue Inhibitor of Metalloproteinase-2) 金屬蛋白酶組織抑制因子-2抗體 50ug/100ug
YY0417R Anti-TIMP-3(Tissue Inhibitor of Metalloproteinase-3) 金屬蛋白酶組織抑制因子-3抗體 50ug/100ug
YY0418R Anti-TIMP-4(Tissue Inhibitor of Metalloproteinase-4) 金屬蛋白酶組織抑制因子-4抗體 50ug/100ug
YY0283R Anti-P2Y1 receptor P2Y1受體抗體 50ug/100ug
MBL
成立于1969年,是日本*家抗體商。公司早期致力于研究血漿蛋白質(zhì)抗體,是抗體研究、發(fā)展和的先鋒者。現(xiàn)在,公司提供3000多種細(xì)胞骨架、致癌基因產(chǎn)品和信號(hào)轉(zhuǎn)導(dǎo)蛋白質(zhì)抗體。1975年,MBL成為日本血漿蛋白質(zhì)的診斷劑的商,之后,公司就致力于開(kāi)發(fā)、免疫診斷試劑,特別是自身免疫性疾病方面的診斷試劑。公司的能力在該領(lǐng)域中得到了*的評(píng)價(jià)。MBL的自身免疫性疾病的診斷劑對(duì)醫(yī)藥界貢獻(xiàn)非常大,該公司產(chǎn)品在自身免疫性疾病方面占據(jù)了日本國(guó)內(nèi)市場(chǎng)80%的份額,在海外市場(chǎng)也同樣受到歡迎。近年來(lái),MBL大力引進(jìn)重組DNA細(xì)胞和細(xì)胞融合技術(shù)來(lái)開(kāi)發(fā)用于疾病診斷和療效觀察的診斷試劑。另外,公司開(kāi)發(fā)了大量分子生物學(xué)和細(xì)胞生物學(xué)研究的產(chǎn)品,包括抗體和可溶性Fas ELISA試劑盒。
YY0283R Anti-P2Y1 receptor P2Y1受體抗體 50ug/100ug